| Literature DB >> 35422968 |
Jorge Dagnino-Leone1, Cristina Pinto Figueroa1, Mónica Latorre Castañeda1, Andrea Donoso Youlton1, Alejandro Vallejos-Almirall1, Andrés Agurto-Muñoz1, Jessy Pavón Pérez1,2, Cristian Agurto-Muñoz1,2.
Abstract
Phycobiliproteins (PBPs) are fluorescent proteins of various colors, including fuchsia, purple-blue and cyan, that allow the capture of light energy in auxiliary photosynthetic complexes called phycobilisomes (PBS). PBPs have several highly preserved structural and physicochemical characteristics. In the PBS context, PBPs function is capture luminous energy in the 450-650 nm range and delivers it to photosystems allowing photosynthesis take place. Besides the energy harvesting function, PBPs also have shown to have multiple biological activities, including antioxidant, antibacterial and antitumours, making them an interesting focus for different biotechnological applications in areas like biomedicine, bioenergy and scientific research. Nowadays, the main sources of PBPs are cyanobacteria and micro and macro algae from the phylum Rhodophyta. Due to the diverse biological activities of PBPs, they have attracted the attention of different industries, such as food, biomedical and cosmetics. This is why a large number of patents related to the production, extraction, purification of PBPs and their application as cosmetics, biopharmaceuticals or diagnostic applications have been generated, looking less ecological impact in the natural prairies of macroalgae and less culture time or higher productivity in cyanobacteria to satisfy the markets and applications that require high amounts of these molecules. In this review, we summarize the main structural characteristics of PBPs, their biosynthesys and biotechnological applications. We also address current trends and future perspectives of the PBPs market.Entities:
Keywords: Bioactive molecules; Biotechnology; PBPs; Protein structure
Year: 2022 PMID: 35422968 PMCID: PMC8983314 DOI: 10.1016/j.csbj.2022.02.016
Source DB: PubMed Journal: Comput Struct Biotechnol J ISSN: 2001-0370 Impact factor: 7.271
Fig. 1(a) Molecular structure of chlorophyll a. (b) Absorption spectrum of Chlorophyll a from Agarophyton chilense. (Chlorphyll a molecule created with pymol from PDB:5B66. Absorption spectrum of Chl a made by the authors, unpublished data).
Fig. 2Structure of Porphyridium purpureum phycobilisome. In pink and light pink PE are shown. In Purple and light purple PC are shown. In turqoise and light turqoise APC are shown. (Phycobilisome image created with pymol from PDB: 6xwk). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 3Absorption spectrum of PBPs from rhodophytes. PE spectrum ref [29]. PC spectrum ref [30]. APC spectrum ref [31]
Fig. 4Structural aligment of α and β subunits of APC, PC, PEC and PE. Green residue shows the cysteine residue which is always chrmoforilated. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Physicochemical, sequence comparision and biological assembly information of PBPs present in the protein data bank (PDB). CB means Cyanobacteria, RA means Red algae. In bold are show the structure used for the sequence and RMSD analysis.
| α | 164 | 17658.04 | 6.73 | 23,7/52,5 | 2, 18 | (αβ)6 | 2VJH | ||
| β | 177 | 18427.16 | 7.52 | ||||||
| α | 164 | 17643.87 | 5.84 | 25/44,5 | 2,06 | (αβ)6 | |||
| β | 184 | 19336.16 | 6.57 | ||||||
| α | 164 | 17751.88 | 5.42 | 27/48,6 | 2, 13 | (αβ)6 | 1EYX | ||
| β | 177 | 18604.18 | 5.15 | ||||||
| α | 164 | 17668.86 | 5.69 | 24,5/46,8 | 2, 13 | (αβ)6 | 1B8D | ||
| β | 177 | 18481.94 | 5.10 | ||||||
| α | 164 | 17638.79 | 5.40 | 24,6/47,6 | 2, 14 | (αβ)6 | 5B13 | ||
| β | 177 | 18408.00 | 5.42 | ||||||
| α | 164 | 17836.07 | 5.70 | 25/50,5 | 2, 14 | (αβ)6 | |||
| β | 177 | 18721.38 | 5.15 | ||||||
| α | 164 | 17805.05 | 5.42 | 27,2/51,1 | 2, 12 | (αβ)3 | 3 V57, 3 V58 | ||
| β | 177 | 18554.18 | 5.43 | ||||||
| α | 162 | 17563.74 | 6.82 | 27,5/44,4 | 2,00 | (αβ)3 | |||
| β | 172 | 18486.95 | 6.72 | ||||||
| α | 162 | 17375.43 | 5.28 | 26,9/52,6 | 2,01 | (αβ)3 | 5OOK | ||
| β | 172 | 18022.41 | 4.94 | ||||||
| α | 162 | 17505.66 | 5.81 | 27,6/54 | 1,91 | (αβ)6 | 1PHN | ||
| β | 172 | 18252.74 | 4.96 | ||||||
| α | 162 | 17662.90 | 7.74 | 23,7/53,2 | 2,03 | (αβ)6 | |||
| β | 172 | 18459.99 | 5.46 | ||||||
| α | 162 | 17585.87 | 5.83 | 24,6/45 | 1,78 | (αβ)6 | |||
| β | 172 | 18066.54 | 4.80 | ||||||
| α | 162 | 17228.34 | 6.56 | 24,6/52,6 | 1,66 | (αβ)6 | 1CPC | ||
| β | 172 | 17920.38 | 5.10 | ||||||
| α | 162 | 17308.34 | 4.64 | 24,7/52,2 | 1,88 | (αβ)6 | |||
| β | 172 | 18124.49 | 5.35 | ||||||
| α | 162 | 17222.29 | 5.79 | 22,9/51,4 | 1,82 | (αβ)6 | 5TOU | ||
| β | 172 | 17842.27 | 5.40 | ||||||
| α | 162 | 17601.87 | 5.83 | 25,7/45,5 | 1,82 | (αβ)6 | |||
| β | 172 | 18093.57 | 4.96 | ||||||
| α | 162 | 17442.70 | 5.36 | 27/52,3 | 1,77 | (αβ)6 | |||
| β | 172 | 18186.67 | 5.12 | ||||||
| α | 162 | 17586.60 | 5.35 | 26,9/49,7 | 2,07 | (αβ)3 | 4F0T | ||
| β | 172 | 18126.47 | 4.98 | ||||||
| α | 162 | 17456.72 | 5.36 | 26,4/52,3 | 1,74 | (αβ)3 | |||
| β | 172 | 18186.67 | 5.12 | ||||||
| α | 162 | 17576.64 | 5.15 | 25,4/53,7 | 1,90 | (αβ)6 | 2BV8 | ||
| β | 172 | 18162.25 | 4.65 | ||||||
| α | 162 | 17506.65 | 6.57 | 27,6/54 | 1,84 | (αβ)6 | 3KVS | ||
| β | 172 | 18224.69 | 4.96 | ||||||
| α | 162 | 17569.78 | 5.81 | 27,5/56,7 | 1,85 | (αβ)6 | 1F99 | ||
| β | 172 | 18000.54 | 4.92 | ||||||
| α | 161 | 17220.67 | 5.07 | 37/64,2 | 1,48 | (αβ)3 | 1ALL | ||
| β | 161 | 17243.70 | 7.67 | ||||||
| α | 161 | 17475.92 | 4.85 | 34,6/62,3 | 1,53 | (αβ)3 | 4RMP | ||
| β | 161 | 17408.82 | 5.15 | ||||||
| α | 161 | 17522.09 | 4.92 | 38,3/66 | 1,41 | (αβ)3 | 2VJT | ||
| β | 161 | 17211.69 | 6.24 | ||||||
| αB | 161 | 17923.45 | 5.44 | 33,7/60,7 | 1,53 | (αβ)3 | 4PO5 | ||
| β | 161 | 17215.64 | 5.43 | ||||||
| α | 161 | 17252.63 | 4.90 | 38,3/65,4 | 1,77 | (αβ)3 | 1B33 | ||
| β | 161 | 17373.84 | 5.45 | ||||||
| α | 161 | 17421.76 | 4.79 | 38/67,5 | 1,57 | (αβ)3 | 4F0U | ||
| β | 161 | 17392.77 | 5.45 | ||||||
| α | 161 | 17538.96 | 4.85 | 39,5/67,9 | 1,38 | (αβ)3 | |||
| β | 161 | 17358.89 | 5.45 | ||||||
| α | 161 | 17519.01 | 4.90 | 38,3/63,6 | 1,42 | (αβ)3 | 5TJF | ||
| β | 161 | 17471.82 | 5.10 | ||||||
| α | 161 | 17496.96 | 5.09 | 35,8/62,3 | 1,47 | (αβ)6 | 1KN1 | ||
| β | 161 | 17443.89 | 5.45 |
Fig. 5Structural level of PBPs. (a) Subunit α, (b) subunit β. (c) heterodimer αβ.
Fig. 6Structural level of PBPs (a) trimer (αβ)3 front view. (b) trimer (αβ)3 side view.
Fig. 7Structural level of PBPs. (a) trimers (αβ)3 face-to-face, (b) hexamer(αβ)6 side view. (c) hexamer(αβ)6 front view.
Fig. 8PBS rod. In blue α subunits. of PC. In purple β subunits of PC. In magenta α subunits of PE. In fuchsia β subunits of PE. In green PCB and PEB molecules. Figure made with pymol using P. Purpureum PBS structure (PDB id: 6KGX).
Bilin lyases family substrate specificity. PCB = phycocyanobilin. PVB = Phycoviolobilin. PEB = Phycoerythrobilin. PUB = Phycourobilin.
| PCB | rpcA | PC-α | Cys-84 | |
| pecA | PEC-α | Cys-84 | ||
| PVB | pecA | PEC-α | Cys-84 | |
| RpcA | PC-α | Cys-84 | ||
| PUB | pecA | PEC-α | Cys-84 | |
| PCB | apcA | APC-α | Cys-81 | |
| apcB | APC-β | Cys-81 | ||
| apcD | APC-αB | Cys-81 | ||
| apcF | APC-β18 | Cys-81 | ||
| cpcB | PC-β | Cys-81 | ||
| rpcB | PC-β | Cys-81 | ||
| pecB | PEC-β | Cys-81 | ||
| PEB | cpeA | PE-α | Cys-81 | |
| cpeB | PE-β | Cys-81 | ||
| PCB | cpcB | PC-β | Cys-153 | |
| pecB | PEC-β | Cys-153 | ||
| PEB | cpeB | PE-β | Cys-153 | |
| cpcB | PC-β | Cys-153 |
Spectroscopic properties of different phycoerythrins. PEB = Phycoerythrobilin. PUB = Phycourobilin.
| C-PE | C-PE I | PEB | PEB | PEB | PEB | PEB | 565 | 575 | |
| C-PE II | PUB | PEB | PEB | PUB | PEB | PEB | 565 | 575 | |
| R-PE | PEB | PEB | PUB | PEB | PEB | 495, 545, 566 | 574 | ||
| B-PE | PEB | PEB | PEB | PEB | PEB | 545, 565 | 576 | ||
Spectroscopic properties of different phycoerythrocyanin. PCB = phycocyanobilin. PVB = Phycoviolobilin.
| PEC | PVB | PCB | PCB | 570 | 625 |
Spectroscopic propierties of different phycocyanins. PCB = phycocyanobilin. PEB = Phycoerythrobilin. PUB = Phycourobilin.
| C-PC | PCB | PCB | PCB | 620 | 640 | |
| R-PC | R-PC-I | PCB | PCB | PEB | 555, 619 | 640 |
| R-PC-II | PEB | PCB | PEB | 533, 545, 615 | 646 | |
| R-PC-III | PEB | PCB | PCB | 560, 603 | 648 | |
| R-PC-IV | PUB | PCB | PCB | 490, 592 | 644 | |
| R-PC-V | PUB | PCB | PEB | 495, 540, 590 | 640 | |
Spectroscopic propierties of different allophycocyanins. PCB = phycocyanobilin.
| Cysα-84 | Cysβ-84 | |||
|---|---|---|---|---|
| PCB | PCB | 651 | 660 | |
| PCB | PCB | 653 | 662 | |
| PCB | PCB | 654 | 679 | |
| PCB | PCB | 654 | 670 | |
Biological effect of PBP and its proposed application. Studies reported between 2019 and 2021.
| PC | Antioxidant | Nephro-protective action on acute kidney injury caused by mercury | ||
| Protective effect on hepatic damage induced by X-ray | ||||
| Diminish the risk of pathologies related to oxidative stress due to high oxidize oil consumption. | ||||
| Attenuation of hepatic ischemia/reperfusion-induced pancreatic islet injury. | ||||
| Prevention action against hepatotoxicity caused by cadmium. | ||||
| Anti-inflammatory | Potential drug development. | |||
| Countermeasure for the cyclophosphamide-Induced Cystitis anticancer chemotherapy | ||||
| Countermeasure reduction by C-PC treatment during colonic cancer radiation therapy. | ||||
| Idiopathic pulmonary fibrosis treatment |
Patents related to phycocyanins in the fields of production, extraction, purification, and biomedical applications.
| Method for inducing the synthesis of PBPs. | ||
| A recombinant photosynthetic protein molecule with a wide range of absorption and its construction process | ||
| Recombinant phycobiliprotein fluorescent protein with large stokes shift and preparation method thereof | ||
| Methods for extracting and purifying | ||
| Extracting and purifying method | ||
| Extraction method of phycobiliprotein of | ||
| Phycobiliprotein draws with many fallers corona discharge reaction unit | ||
| Technology for separating and purifying phycobiliprotein from | ||
| Method for extracting and purifying phycobiliprotein and purified phycocyanin | ||
| The process of achieving the highest degree of drug's purity of c-phycocyanin from | ||
| Kit for early detection of liver cancer and preparation method thereof | ||
| A kind of utilize recombinant detection reagent bar of fluorescence phycobniliprotein subunit and preparation method thereof | ||
| Composition containing phycobiliprotein polysaccharide extract and use of a composition containing phycobiliprotein polysaccharide extract | ||
| Preparation method of phycobiliprotein polypeptide powder | ||
| Antitumor drug carrier and application method thereof | ||
| Preparation method of double-network hydrogel loaded with phycobiliprotein | ||
| Anti-enteritis | ||
| Compositions for protecting skin comprising DNA repair enzymes and phycobiliprotein | ||
| Heart valve prosthesis, preparation method, and | ||
| Phycocyanin composition for use in inhibiting bone resorption | ||
| Novel material based on natural diatom shell and phycobiliprotein and application |